Introduction
Brivaracetam(BRV) is the latest anti-epileptic drug (AED) approved for adjunctive therapy of focal onset seizures and was introduced to the German market in February 2016. Similarly to Levetiracetam (LEV), BRV acts through binding synaptic vesicle protein 2 A which plays a role in synaptic vesicle trafficking and is distributed almost ubiquitously in the central nervous system. Orally administered BRV is resorbed completely and quickly and is metabolized via cytochrome P450-dependent and -independent pathways with its metabolites being eliminated renally. So far, ten metabolites have been described in patients taking BRV [1] . In previous studies, commonly reported adverse events (AEs) associated with BRV treatment included fatigue, somnolence or dizziness as well as behavioral AEs like irritability [2] .
Here, for the first time, we report the occurrence of a peculiar, sulfuric body odor under BRV monotherapy.
Case report
A 57-year-old male patient who had been diagnosed with structural epilepsy in 1998 presented with potential behavioral side effects under LEV-monotherapy. He reported subjective memory impairment and increased irritability, which he associated with his current LEV-medication. Given the fact that he had been seizure free on LEV-monotherapy (500 mg bid) for more than ten years, an immediate switch to BRV (25 mg bid) was initiated, as previous reports suggested that, in some cases, behavioural effects associated with LEV resolved after switching to BRV [3] . The patient was informed that BRV monotherapy was an individual off-label prescription.
Four weeks after the switch, the patient presented ahead of schedule to our outpatient clinic again. No prior medical consultations had been sought in this period. The patient reported that he had developed an unpleasant body odor, starting about 16 h after his first BRV intake. The body odor had persisted over the entire three weeks of BRV intake, and according to the patient had faded within few days after self-implemented discontinuation of BRV and switch back to LEV. The patient characterized the odor as sulfuric, similar to the odor urine can adopt after consumption of asparagus, and also the patient's urine reportedly adopted the same odor. His wife confirmed this strong and unpleasant smell.
The patient had been seizure free over the entire period of BRV intake and reported that his irritability and memory had improved significantly after the switch from LEV to BRV.
However, as the patient again reported an impaired memory function and irritability under LEV, a gradual switch to monotherapy with LTG was implemented.
The patient had never suffered any psychiatric comorbidity, nor did he take any medication concomitantly to BRV or to the other AEDs. His glomerular filtration rate was 74 ml/min (Chronic kidney disease stage 2, determined on the day of first BRV intake), and apart from that, no other comorbidity was described.
Discussion
Here we report an unpleasant, sulfuric body odor as a potential BRV-associated adverse event. There was a close temporal relationship between BRV intake and the development and the occurrence of the described olfactory sensation. No other factors such as comorbidities, change of nutrition or comedications which might have also caused this phenomenon were described. Psychotropic effects associated with BRV or olfactory aura might be possible other causes of the reported sensation. However, the continuous and steady presence and confirmation of the odor by the patient's wife make both rather unlikely.
With a quick absorption (C(max) in plasma within 1.5 h) and a terminal half-life of 9 h the pharmacokinetics of BRV seem compatible with the temporal relationship of the development of the described adverse event. The described emergence of the odor in the patient's urine seems plausible due to the entirely renal elimination of BRV and its metabolites [1] .
It is possible that a metabolite of BRV was the cause for this olfactory phenomenon.
Due to the olfactory similarity of the smell after BRV intake with to the odor of urine after consumption of asparagus, it seems plausible to hypothesize a chemical similarity between the responsible metabolites.
In asparagus, these odor-associated substances seem to be sulphur compounds that are metabolites of asparagusic acid, and among these seemingly in particular dimethyl sulphide [4] .
Among the known metabolites of BRV, only one is known to contain a sulphur group (M6). M6 is a taurine conjugate of the most common metabolite of BRV (M9), was not detectable in plasma and constituted only 1% of the metabolized BRV in urine samples in a pharmacological study on BRV [1] .
It is not probable that the taurine group of this substance causes body odour, however, the patient presented had a moderate renal dysfunction that might explain an accumulation of some metabolites.
Thus, future pharmacological studies investigating rare pathways and variants in the metabolization of BRV are of interest to explain this rare adverse event during therapy with BRV, and therefore to be able to potentially be able to identify patients at risk for these AEs.
